154 related articles for article (PubMed ID: 8843291)
1. In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.
Gnarpe J; Eriksson K; Gnarpe H
Antimicrob Agents Chemother; 1996 Aug; 40(8):1843-5. PubMed ID: 8843291
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations.
Nyström-Rosander C; Hultén K; Gustavsson I; Cars O; Engstrand L; Hjelm E
Scand J Infect Dis; 1997; 29(5):513-6. PubMed ID: 9435043
[TBL] [Abstract][Full Text] [Related]
3.
Kohlhoff SA; Huerta N; Hammerschlag MR
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509942
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
Hammerschlag MR; Qumei KK; Roblin PM
Antimicrob Agents Chemother; 1992 Jul; 36(7):1573-4. PubMed ID: 1324650
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of trovafloxacin against Chlamydia pneumoniae.
Roblin PM; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 1997 Sep; 41(9):2033-4. PubMed ID: 9303410
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.
Agacfidan A; Moncada J; Schachter J
Antimicrob Agents Chemother; 1993 Sep; 37(9):1746-8. PubMed ID: 8239579
[TBL] [Abstract][Full Text] [Related]
7. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Jan; 42(1):194-6. PubMed ID: 9449287
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.
Kuo CC; Jackson LA; Lee A; Grayston JT
Antimicrob Agents Chemother; 1996 Nov; 40(11):2669-70. PubMed ID: 8913488
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae.
Kohlhoff SA; Huband MD; Hammerschlag MR
Antimicrob Agents Chemother; 2014 Dec; 58(12):7595-6. PubMed ID: 25288086
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR
Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.
Freidank HM; Losch P; Vögele H; Wiedmann-Al-Ahmad M
Antimicrob Agents Chemother; 1999 Jul; 43(7):1808-10. PubMed ID: 10390251
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.
Kohlhoff SA; Roblin PM; Reznik T; Hawser S; Islam K; Hammerschlag MR
Antimicrob Agents Chemother; 2004 May; 48(5):1885-6. PubMed ID: 15105151
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cethromycin, a novel antibacterial ketolide, against Chlamydia pneumoniae.
Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
J Antimicrob Chemother; 2003 Sep; 52(3):497-9. PubMed ID: 12917246
[TBL] [Abstract][Full Text] [Related]
14. Association of the in vitro susceptibility of clinical isolates of chlamydia trachomatis with serovar and duration of antibiotic exposure.
Zheng H; Xue Y; Bai S; Qin X; Lu P; Yang B
Sex Transm Dis; 2015 Mar; 42(3):115-9. PubMed ID: 25668641
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Jun; 42(6):1515-6. PubMed ID: 9624507
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae.
Welsh L; Gaydos C; Quinn TC
Antimicrob Agents Chemother; 1996 Jan; 40(1):212-4. PubMed ID: 8787907
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
Antimicrob Agents Chemother; 2003 Mar; 47(3):1135-6. PubMed ID: 12604555
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 1998 Apr; 42(4):951-2. PubMed ID: 9559818
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections.
Pitt R; Alexander S; Ison C; Horner P; Hathorn E; Goold P; Woodford N; Cole MJ
J Antimicrob Chemother; 2018 Mar; 73(3):680-686. PubMed ID: 29207004
[TBL] [Abstract][Full Text] [Related]
20. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
